Document is current

Article History

Received: 3 November 2018

Accepted: 25 March 2019

First Online: 25 April 2019

Ethics approval and consent to participate

: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating centre (Sant’Andrea Hospital, Rome Italy) on 25 September, 2006 (n. 43/2006) and subsequently by the ethics committee of each participating centre. Participants provided an informed consent.

: Not applicable.

: AS: consulting fees from Astra-Zeneca, Boehringer–Ingelheim, Eli Lilly; lecture fees from Boehringer–Ingelheim, Eli Lilly, Sanofi-Aventis; grant support from Astra-Zeneca. GPe: consulting fees from Astra-Zeneca, Boehringer–Ingelheim, Eli Lilly; lecture fees from Astra-Zeneca, Boehringer–Ingelheim, Eli Lilly, Merck-Sharp&Dohme, Novo Nordisk. EO: consulting fees from Boehringer–Ingelheim, Eli Lilly, Novo Nordisk, Sanofi-Aventis; lecture fees from Abbot, Astra-Zeneca, Eli Lilly, Lifescan, Sanofi-Aventis, Takeda. EB: consulting fees from Abbott, Astra-Zeneca, Boehringer–Ingelheim, Bruno Farmaceutici, Eli Lilly; lecture fees from Bristol-Myers Squibb, Eli Lilly, Janssen, Merck-Sharp&Dohme, Novartis, Novo Nordisk, Roche, Sanofi-Aventis, Servier, Takeda; grant support from Astra-Zeneca, Genzyme, Menarini Diagnostics, Novo Nordisk, Roche, Takeda. CF: none reported. RT: consulting fees from Boehringer–Ingelheim, Sanofi-Aventis; lecture fees from Astra-Zeneca, Boehringer–Ingelheim, Eli Lilly, Janssen, Medtronic, Novartis, Novo Nordisk, Sanofi-Aventis; grant support from Astra-Zeneca, Boehringer–Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi-Aventis. MV: none reported. FC: lecture fees from Astra-Zeneca, Boehringer–Ingelheim, Merck-Sharp&Dohme, Sanofi-Aventis, Takeda. OL: consulting fees from Astra-Zeneca, Boehringer–Ingelheim; lecture fees from Astra-Zeneca, Eli Lilly, Merck-Sharp&Dohme, Sigma-Tau, Sanofi-Aventis, Takeda; grant support from Astra-Zeneca. MB: lecture fees from Abbot, Astra-Zeneca, Mundi Pharma, Novo Nordisk, Sanofi-Aventis; grant support from Sanofi-Aventis. AN: consulting fees from Eli Lilly, Novo Nordisk; lecture fees from Eli Lilly, Novo Nordisk; grant support from AlfaSigma, Artsana, Astra-Zeneca, Eli Lilly, Novo Nordisk, Sanofi-Aventis. GPu: lecture fees from Astra-Zeneca, Eli Lilly, Sigma-Tau, Takeda.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.